# US 2026/0248880 A1 · Nanoparticle compositions and uses thereof for reactivation of latent hiv

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0248880 A1
- Document ID: US20260248880A1
- Status: Published application
- Kind: A1
- Application number: 19/159,195
- Filed: 2024-02-26
- Published: 2026-08-27
- Earliest claimed: 2023-02-26
- Assignees: The Wistar Institute of Anatomy and Biology; The Trustees of the University of Pennsylvania
- Applicants: The Wistar Institute of Anatomy and Biology; The Trustees of the University of Pennsylvania
- Inventors: Luis Montaner; Daniel Claiborne; Hamideh Parhiz; Tyler E. Papp
- Web page: https://patentgrep.com/patent/US20260248880A1

## CPC

- A61K 38/162: {from virus}
- C07K 14/005: from viruses
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 39/12: Viral antigens
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61P 31/18: for HIV
- C07K 16/2812: {against CD4}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are nanoparticles comprising a messenger RNA (mRNA) encoding an HIV tat protein and methods of administering the nanoparticles to a patient for treating HIV.

## Claims

### Claim 1

A lipid nanoparticle (LNP) encapsulating an mRNA comprising a nucleotide sequence encoding an HIV Tat protein.

### Claim 2 (depends on 1)

The lipid nanoparticle of claim 1, wherein the HIV tat protein comprises the amino acid sequence of SEQ ID NO: 1, or a fragment of the sequence of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The lipid nanoparticle of claim 1, wherein the sequence encoding the HIV tat protein comprises the sequence of SEQ ID NO: 2, or a sequence sharing at least 70% identity with SEQ ID NO: 2.

### Claim 4 (depends on 1)

The lipid nanoparticle of claim 1, further comprising an antibody or peptide that specifically binds CD4, CCR5, or CXCR4 on a target immune cell.

### Claim 5 (depends on 1)

The lipid nanoparticle of claim 1, wherein the mRNA comprises (i) a 3′ UTR; (ii) a 5′ UTR; and/or (iii) a polyA tail.

### Claim 6 (depends on 1)

The lipid nanoparticle of claim 1, wherein the polynucleotide comprises a 5′ terminal cap structure.

### Claim 7 (depends on 1)

The lipid nanoparticle of claim 1, wherein the mRNA comprises at least one chemically modified nucleotide or nucleoside.

### Claim 8 (depends on 7)

The lipid nanoparticle of claim 7, wherein the at least one chemically modified nucleotide or nucleoside is pseudouridine, Nl-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, or a combination thereof.

### Claim 9 (depends on 1)

A composition comprising the lipid nanoparticle of claim 1 and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the composition is formulated for intravenous delivery.

### Claim 11 (depends on 1, 9)

A method of treating HIV in a subject in need thereof, the method comprising administering the nanoparticle of claim 1 or the composition of claim 9 to the subject.

### Claim 12 (depends on 11)

The method of claim 11, further comprising administering an anti-retroviral therapy to the subject.

### Claim 13 (depends on 1, 9)

A method of reactivating HIV in a latently infected immune cell, the method comprising contacting the immune cell with the nanoparticle of claim 1 or the composition of claim 9, optionally wherein the immune cell is a CD4+ T cell.

### Claim 14 (depends on 13)

The method of according to claim 13, wherein contacting the immune cell with the nanoparticle does not result in activation of the immune cell, optionally wherein activation of the immune cell is determined by measuring surface expression of one or more of CD69, CD25, HLA-DR, CD71, CD26, CD27, CD28, CD30, CD154, CD40L, CD134, CD44, and CD62L.

### Claim at position 15

15-16. (canceled)
